Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

preview_player
Показать описание
An expert in non–small cell lung cancer reviews the off-label use of crizotinib in patients with METex14 mutations and the unmet needs in this patient population.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Off-Label Crizotinib for 0:03:24

Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

Crizotinib for First 0:00:56

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Off-label medication use 0:02:42

Off-label medication use in lung cancer

GRACE Targeted Therapies 0:02:02

GRACE Targeted Therapies Lung Cancer 2021 - Second Line ROS1 Medication Off-Label

Current treatment landscape 0:02:21

Current treatment landscape for ALK-positive NSCLC

Q&A: Cabozantinib for 0:02:52

Q&A: Cabozantinib for ROS1 after Progression on Crizotinib - Targeted Therapies in Lung Cancer 2...

ROS1-Rearranged NSCLC 0:04:55

ROS1-Rearranged NSCLC

Late Relapse of 0:03:28

Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared by Crizotinib

Targeting HER2, BRAF, 0:21:10

Targeting HER2, BRAF, KRAS, MET

2023 Best of 0:30:32

2023 Best of Lung: Targeted Therapies in Lung Cancer

Targeting ALK - 0:45:52

Targeting ALK - From Discovery to Frontline Treatment

Expanding access to 0:06:43

Expanding access to crizotinib using a biomarker-driven approach

ONLY ON 2: 0:03:15

ONLY ON 2: Diabetes Drug That Kills Cancer?

Genomics and Clinical 0:16:22

Genomics and Clinical Trials. How might this work? Biological, logistical and cultural challenges

Segment 2: Molecular 0:26:57

Segment 2: Molecular Targets in NSCLC

ALK fusion-positive NSCLC: 0:19:18

ALK fusion-positive NSCLC: International approaches to management | Panel discussion

The Role of 0:06:02

The Role of Multikinase TKIs for NSCLC

ROS1 ALK Initial 1:07:25

ROS1 ALK Initial Treatment, Acquired Resistance with Melina Marmarelis, MD and Charu Aggarwal, MD

Improving Outcomes in 1:02:02

Improving Outcomes in Molecularly Altered NSCLC Through Precision Testing and Treatment

Managing CNS Disease 0:08:30

Managing CNS Disease in ALK-Rearranged NSCLC

Expert highlights: Targeted 0:09:57

Expert highlights: Targeted therapy for ALK-, RET- and MET-driven NSCLC | Tejas Patil

Evolving Approaches for 0:04:41

Evolving Approaches for Treating ALK-Positive NSCLC

Therapeutic strategy in 0:22:40

Therapeutic strategy in GIST tumors

Treatment Options & 0:10:50

Treatment Options & Study Data for Patients with ROS1+ NSCLC- Targeted Therapies in Lung Cancer ...